v3.25.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (1,967,611) $ (2,562,330)
Adjustments to reconcile net loss to net cash used in operating activities    
Amortization of debt discount 94,213 605,630
Stock-based compensation 485,831 292,552
Changes in operating assets and liabilities:    
Accounts payable and accrued expenses 706,478 90,994
Accrued compensation (152,023)
Due from Chromocell Corporation (45,786)
Prepaid expenses 48,963 (220,930)
Net Cash Used In Operating Activities (632,126) (1,991,893)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from loan payable, net of debt discount 250,000
Payment of bridge loan, net of debt discount (214,757)
Common stock issued for cash 5,972,000
Recission of common stock (91,512)
Net Cash Provided By Financing Activities 250,000 5,665,731
NET CHANGE IN CASH (382,126) 3,673,838
CASH AT BEGINNING OF YEAR 513,443 96,391
CASH AT END OF YEAR 131,317 3,770,229
Supplemental cash flow information:    
Cash paid for income taxes
Cash paid for interest expense 11,250
NONCASH INVESTING AND FINANCING ACTIVITIES:    
Debt discount from common stock issued for extension of bridge loan 447,779
Conversion of notes to common stock 1,362,821
Transfer of liabilities to Chromocell Corporation for Series C Preferred Stock 2,153,362
Offering costs recorded to debt discount $ 26,875